DNAtrix, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Houston TX United States (2005)

Organization Overview

First Clinical Trial
2009
NCT00805376
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

DNAtrix, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (1 trial)

Tasadenoturev (4 trials)

Drugs in Phase 1 Trials (3)

ad5-dnx-2401 (1 trial)

dnx-2440 (2 trials)

interferon gamma-1b (actimmune) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 2)

Brain Neoplasms (Phase 2)

Central Nervous System Diseases (Phase 1)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Gliosarcoma (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Histologic Type (Phase 2)

Neoplasms, Nerve Tissue (Phase 2)

Neoplasms, Neuroepithelial (Phase 2)

Nervous System Diseases (Phase 2)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5